Akeso Biopharma’s Ivonescimab Outshines Keytruda in NSCLC Trial, Raises FDA Concerns
FiercePharma.com has reported on the reactions of multinational corporation executives to the recent news that...
Gilead and Arcus Biosciences Report Positive Interim Phase II Data for Domvanalimab Combo in GI Cancers
Gilead (NASDAQ: GILD) and Arcus Biosciences (NYSE: RCUS) have announced interim Phase II data for...
Changchun GeneScience to Distribute TWi Pharma’s Megestrol in China and Southeast Asia
Changchun GeneScience Pharmaceutical Co., Ltd, a biopharmaceutical company based in China, has entered into an...
China’s NHSA and MoF Plan Expansion of Long-term Care Insurance System Pilot Program
The National Healthcare Security Administration (NHSA) and the Ministry of Finance (MoF) have jointly issued...
Eli Lilly’s KRAS Inhibitor Olomorasib Shows Promise in Phase I/II Trial for Advanced Solid Tumors
Eli Lilly and Company (NYSE: LLY) has presented an update on a Phase I/II clinical...
Shenzhen’s Draft Proposal for VBP Drug Procurement and Medical Insurance Fund Management Released
The Healthcare Security Administration (HSA) Bureau of the Shenzhen municipality has released a “Shenzhen Drug...
Bristol Myers Squibb’s Krazati Meets Primary Endpoint in Late-Stage Lung Cancer Study
Bristol Myers Squibb (BMS; NYSE: BMY) has announced that a late-stage study for its KRAS...
Hygea Medical’s Subsidiary Gets Green Light for Innovative Intrahepatic Puncture Instrument in China
Hygea Medical Technology Co., Ltd, a China-based medical device company, has announced that its subsidiary,...
GenScript Shares Slide on US Congressional Request for FBI Investigation
Shares of GenScript Biotechnology Co., Ltd (HKG: 1548), a China-based Contract Development and Manufacturing Organization...
Pfizer’s Lorbrena Outperforms Xalkori in 5-Year ALK-Positive NSCLC Follow-Up
Pfizer Inc. (NYSE: PFE) has announced the release of five-year follow-up data for its kinase...
Astellas Resubmits FDA Application for Vyloy as Treatment for CLDN18.2-Positive Cancer
Astellas Pharma Inc. (TYO: 4503), a Japanese pharmaceutical company, has resubmitted its first-in-class anti-CLDN18.2 biologic...
Simcere Pharma’s Suvemcitug Shows Positive Results in Platinum-Resistant Ovarian Cancer Study
Simcere Pharmaceutical Group (HKG: 2096), a biopharmaceutical company based in China, has presented updated data...
Ascentage Pharma’s APG-2449 Shows Positive Results in ROS1 and ALK Positive NSCLC at ASCO 2024
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in Suzhou, has announced a wall poster...
Jacobio Pharma’s KRAS G12C Inhibitor Combo Shows Promising Results in NSCLC at ASCO 2024
Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, presented updated data at the...
NMPA Announces Digitalization of Medical Device Regulatory Documents
The National Medical Products Administration (NMPA) has announced a transition to digitalize regulatory documentation for...
China’s NHSA Launches New Procedures for Drug Catalogue Attribution Identification
The National Healthcare Security Administration (NHSA) has issued the “Procedures for Identification of Drug and...
Innovent Biologics Presents Clinical Data for Pipeline Candidates at ASCO 2024
Innovent Biologics Inc., (HKG: 1801), a biopharmaceutical company based in China, presented updates on several...
Andon Health’s COVID-19 Trio Test Kit and OTC Antigen Test Win FDA Approval
Andon Health Co., Ltd (SHE: 002432), a healthcare company based in China, has announced that...
Nanjing Kingfriend Biochemical Gets FDA Nod for Dacarbazine Manufacture at Sagent Facility
Nanjing Kingfriend Biochemical Pharmaceutical Co., Ltd (SHA: 603707), a Chinese pharmaceutical company, has announced that...
Gilead’s Trodelvy Misses Overall Survival Endpoint in Late-Stage Urothelial Cancer Study
Gilead (NASDAQ: GILD) has announced that a late-stage study for its antibody-drug conjugate (ADC) Trodelvy...